Ondine Biomedical (LSE:OBI) has agreed a strategic data collaboration with Mela Solutions, whose Medicus platform is used in 90% of NHS intensive care units. The partners plan a first-year pilot in 6 to 10 large ICUs to assess the clinical and financial impact of Ondine's Steriwave nasal photodisinfection.
What was announced
Ondine Biomedical Inc. (LSE:OBI) said on 29 September 2026 that it has entered a strategic data evaluation Partnership with Mela Solutions Ltd. The aim is to measure the financial and clinical impact of Steriwave across NHS intensive care units and to "verify Steriwave's cost-benefit ratio".
This is a data collaboration with Mela, not a Supply contract with the NHS or any NHS trust. The announcement discloses no contract value, revenue, or financial terms.
The pilot and the numbers
Mela has been supporting UK healthcare for more than 25 years. Its Medicus clinical information platform is embedded in 90% of NHS ICUs, covering about 4,500 ICU beds across roughly 300 adult critical care units.
The partners are targeting 6 to 10 hospitals in the first year, each with 30 or more ICU beds. The participating sites could together cover up to 20,000 critical care admissions a year. Based on the disclosed figures, 6 to 10 sites of at least 30 beds each would mean a minimum of 180 to 300 beds, or roughly 4% to 7% of the NHS ICU beds Medicus covers. The evaluation will look at workflow integration, clinical impact, cost savings and whether the product frees up bed capacity.
Ondine says work to customise the data platform is under way. The intention is that NHS trusts can compare Steriwave results against their own historical ICU baseline data. The company says this would support decisions on commercial deployment "within weeks rather than years", though no start date for the pilot is given.
The announcement cites the following NHS context figures:
- 16% of ICU patients acquire a hospital infection.
- An average ICU bed treats about 65 patients a year.
- A critical care bed costs about £1,881 a day.
- Ventilator-associated pneumonia costs about £9,000 per patient.
- Infectious diseases cost NHS secondary care nearly £6bn in 2023-24.
Background
Steriwave is a light-activated antimicrobial treatment. A photosensitising agent is applied to the nose by a healthcare professional and then activated with red light. It works through non-antibiotic oxidative pathways, which Ondine says lowers the potential for microbial resistance. In the UK, Steriwave is distributed by Mölnlycke Health Care.
Ondine cites two studies in support of the product:
- The Phase 3 LANTERN trial of 5,188 patients across 18 hospitals in Canada and the US, which it says met its primary endpoint with a 40.5% reduction in surgical site infections.
- The SMURF feasibility study at Royal Columbian Hospital, covering 227 patients, which it says showed a 39.5% reduction in ICU pneumonia rates and a statistically significant fall in nasal pathogen burden.
Chief Executive Carolyn Cross said that "preventing ICU-acquired infections may cost-effectively increase effective NHS ICU capacity without requiring additional beds". Edward Willans, Managing Director of Mela Solutions, said the partnership shows how data infrastructure "can accelerate the evidence-based evaluation and adoption of proven clinical innovations across the NHS".
What to watch next
The key questions are practical ones. The announcement does not say which trusts will take part, when the first sites will start, or how the pilot will be paid for. It also does not say whether pilot sites would buy Steriwave through Mölnlycke during the evaluation.
Results from the pilot, and any decisions by trusts to adopt Steriwave afterwards, would be the next markers of commercial progress. The size of the opportunity described by the company depends on trusts choosing to deploy the product once the evaluation is complete, which is not assured.






Please wait processing your request...